CDEK
← All organizations

Apellis Pharmaceuticals, Inc.

For profitContributed to NMEWebsite ↗

Also known as: Apellis Pharmaceuticals, Inc. | APELLIS PHARMS

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 3

First clinical trial

Nov 1, 2014

First marketed drug

May 14, 2021

First NDA

May 14, 2021

Last known activity

Dec 31, 2025

Timeline

2000s

  1. Jun 1, 2008

    Apellis Pharmaceuticals, Inc.— Founded

2010s

  1. Nov 20, 2014

    Potentia Pharmaceuticals— Acquired

2020s

  1. May 14, 2021

    pegcetacoplan— Marketing Organization

  2. May 14, 2021

    pegcetacoplan— NDA Organization

  3. May 14, 2021

    pegcetacoplan— NDA Secondary Org

Drugs by trial phase (5 distinct, 28 trials)

Phase 3 (2 own, 0 via acquisition)

Phase 2 (2 own, 0 via acquisition)

Phase 1 (0 own, 1 via acquisition)

Indications

Studied for

Marketed drugs (1)

Subsidiaries (1 direct, 1 total across the full acquisition tree)

Recent trials (31)

Details

Founded
Crestwood, KY, US Jun 1, 2008
First NDA
May 14, 2021
Last known activity
Dec 31, 2025

Designations held

  • Orphan drug
  • Fast track
  • Priority review